Visit RheumNow's Booth at #ACR23 https://t.co/7HuNpWtf0M https://t.co/INtMGvEkA3

• Visit RheumNow's Booth at ACR Convergence 2023 | RheumNow

Evidence of window of opportunity concept in PsA. Certainly >52 weeks delay associates with worse outcomes. <12 weeks and 12-52 weeks similar. Abstr#1641 #ACR23 @RheumNow https://t.co/fMb3D9zl8B https://t.co/rHu29Eflo0

FDG-PET uptake at baseline in GCA predicts future risk of future thoracic aneurysm In print here: https://t.co/2SQm18y6zP Could this help stratify aneurysmal screening? #ACR23 ABST1647 @RheumNow https://t.co/p1Dhkm2WTX

• Association Between Vascular 18F-Fluorodeoxyglucose Uptake at Diagnosis and Cha…

It's OK to use TNFi in RA-ILD! VA study 1000+ pts using Target Trial Emulation framework: TNFi vs nonTNFi biologics/JAKi followed for 3 years. NO differences in respiratory hospitalizations or deaths or all cause mortality. abst#1582 #ACR23 #ACRbest @rheumnow https://t.co/aI2SmMrLPE

Wolfgang Schmidt presenting @eular_org large vessel vasculitis imaging recommendations at #ACR23, acknowledging @ACRheum on the way. Great to see a master (& a new ACR Master) navigate with clarity, uniting different sides of the Atlantic. @RheumNow https://t.co/hyAcX8GSWf

What do we see in GCA, with serial PET/CT after five years? In this Australian cohort: cranial uptake disappears extra-cranial uptake sometimes emerges (but not for pts on DMARDs) Still understanding the trajectory of smouldering activity @tonysammel #ACR23 ABST1645 @RheumNow https://t.co/mKB3mjBuBt

Factors predicting fatigue in RA differ by disease activity. Synovial lining hyperplasia and synovial lymphocytic inflammation on histology were key factors. @rheumnow #ACR23 session 13M148 https://t.co/yPBZX2Rxft

RA-ILD: the study that exonerates TNFi ? TNFi vs. other BioDMARDs/JAK do not increase risk of death or hospitalization over 1 and 3 yrs follow up. No subgroups stand out VHA cohort, 50% smokers No info on ILD patterns or disease trajectory ABST1582 @RheumNow #ACR23 https://t.co/frv16oRLqv

Lovering et al. Synergestic effect of RA and CVD on dementia risk. 35% increased risk RA, 89% increased risk RA+CVD. Abstr#1628 #ACR23 @RheumNow https://t.co/Brj8XrG2o4

#ClinicalPearl or #pathology pearl? Using synovial #biopsies to guide therapy in #RA #RCTs is a reality. But likely #fibrotic #phenotype won’t respond and #lympho_myeloid has more RA damage. #ACR23 session 13M140 #Precision #medicine #ACRbest ⁦@ACRheum⁩ ⁦@RheumNow⁩ https://t.co/DmI9dNpu8w

PET/CT real-world performance in GCA diagnosis, Sydney @tonysammel: comparable to other modalities can optimize for sen or spec based on managing equivocal results ?some steroid confounding but definitely one of 3 complementary imaging options for GCA #ACR23 ABST1646 @RheumNow https://t.co/FvdLMvpqEU

#ACR23 Abstr#1634 Promising therapy for two #Sjogren groups: 1 (high ESSDAI & ESSPRI) & 2 (low ESSDAI, high ESSPRI). Phase 2 RCT of Iscalimab (anti-CD40ab) showed more ISC-treated pts met the primary endpoint (ESSDAI and ESSPRI changes at WK24) vs PBO. Going to Phase 3 @RheumNow https://t.co/3bN3IS1zCO